File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Extent of lymphadenectomy for Barrett's cancer

TitleExtent of lymphadenectomy for Barrett's cancer
Authors
KeywordsBarrett esophagus
lymphadenectomy
lymphatic metastasis
esophagogastric junction
Issue Date2019
PublisherAME Publishing Company. The Journal's web site is located at http://tgh.amegroups.com/index
Citation
Translational Gastroenterology and Hepatology, 2019, v. 4, p. article no. 36 How to Cite?
AbstractAbstract: Adenocarcinoma of the esophagus and esophagogastric junction (EGJ) has become the predominant histological cell type in western countries due to the prevalence of obesity, gastroesophageal reflux disease and Barrett’s esophagus. There is some evidence that this is increasing in the East as well. Surgery aims at achieving an R0 resection with clear margins, together with adequate and appropriate lymphadenectomy. Siewert type I and II cancers are more likely to be associated with Barrett’s esophagus (especially in western countries), while type III cancers are mostly proximal gastric cancers that have grown upwards to involve the EGJ. For type I cancers, most surgeons would perform an esophagectomy, with at least an infra-carinal lymphadenectomy. It is more controversial for type II tumors, with some surgeons preferring an esophagectomy, while others may opt for a proximal or total radical gastrectomy via an abdominal approach. All procedures can be performed using open or minimally invasive methods. In addition to oncologic reasons, the chosen surgical approach also depends on expertise available, safety issues, and postoperative quality-of-life considerations. More data are needed in this area. How to integrate knowledge and also multimodality treatment strategies is an active area of research.
Persistent Identifierhttp://hdl.handle.net/10722/305454
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, CL-
dc.contributor.authorLaw, S-
dc.date.accessioned2021-10-20T10:09:37Z-
dc.date.available2021-10-20T10:09:37Z-
dc.date.issued2019-
dc.identifier.citationTranslational Gastroenterology and Hepatology, 2019, v. 4, p. article no. 36-
dc.identifier.issn2415-1289-
dc.identifier.urihttp://hdl.handle.net/10722/305454-
dc.description.abstractAbstract: Adenocarcinoma of the esophagus and esophagogastric junction (EGJ) has become the predominant histological cell type in western countries due to the prevalence of obesity, gastroesophageal reflux disease and Barrett’s esophagus. There is some evidence that this is increasing in the East as well. Surgery aims at achieving an R0 resection with clear margins, together with adequate and appropriate lymphadenectomy. Siewert type I and II cancers are more likely to be associated with Barrett’s esophagus (especially in western countries), while type III cancers are mostly proximal gastric cancers that have grown upwards to involve the EGJ. For type I cancers, most surgeons would perform an esophagectomy, with at least an infra-carinal lymphadenectomy. It is more controversial for type II tumors, with some surgeons preferring an esophagectomy, while others may opt for a proximal or total radical gastrectomy via an abdominal approach. All procedures can be performed using open or minimally invasive methods. In addition to oncologic reasons, the chosen surgical approach also depends on expertise available, safety issues, and postoperative quality-of-life considerations. More data are needed in this area. How to integrate knowledge and also multimodality treatment strategies is an active area of research.-
dc.languageeng-
dc.publisherAME Publishing Company. The Journal's web site is located at http://tgh.amegroups.com/index-
dc.relation.ispartofTranslational Gastroenterology and Hepatology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBarrett esophagus-
dc.subjectlymphadenectomy-
dc.subjectlymphatic metastasis-
dc.subjectesophagogastric junction-
dc.titleExtent of lymphadenectomy for Barrett's cancer-
dc.typeArticle-
dc.identifier.emailWong, CL: wongcly@hku.hk-
dc.identifier.emailLaw, S: slaw@hku.hk-
dc.identifier.authorityLaw, S=rp00437-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.21037/tgh.2019.05.07-
dc.identifier.scopuseid_2-s2.0-85071659317-
dc.identifier.hkuros328115-
dc.identifier.volume4-
dc.identifier.spagearticle no. 36-
dc.identifier.epagearticle no. 36-
dc.identifier.isiWOS:000470125700009-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats